Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 8/2016

Open Access 01-11-2016 | Original Paper

Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain

Authors: Manel Mata-Cases, Marc Casajuana, Josep Franch-Nadal, Aina Casellas, Conxa Castell, Irene Vinagre, Dídac Mauricio, Bonaventura Bolíbar

Published in: The European Journal of Health Economics | Issue 8/2016

Login to get access

Abstract

We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications.
Appendix
Available only for authorised users
Literature
1.
Ruiz-Ramos, M., Escolar-Pujolar, A., Mayoral-Sanchez, E., Corral-San Laureano, F., Fernandez-Fernandez, I.: Diabetes mellitus in Spain: death rates, prevalence, impact, costs and inequalities. Gac. Sanit. 20(Suppl 1), 15–24 (2006)CrossRefPubMed
2.
Gonzalez, P., Faure, E., Del Castillo, A.: Cost of diabetes mellitus in Spain. Med. Clin. (Barc.) 127(20), 776–784 (2006)CrossRef
3.
Ballesta, M., Carral, F., Olveira, G., Giron, J.A., Aguilar, M.: Economic cost associated with type II diabetes in Spanish patients. Eur. J. Health Econ. 7(4), 270–275 (2006)CrossRefPubMed
4.
Soriguer, F., Goday, A., Bosch-Comas, A., Bordiu, E., Calle-Pascual, A., Carmena, R., Casamitjana, R., Castano, L., Castell, C., Catala, M., Delgado, E., Franch, J., Gaztambide, S., Girbes, J., Gomis, R., Gutierrez, G., Lopez-Alba, A., Martinez-Larrad, M.T., Menendez, E., Mora-Peces, I., Ortega, E., Pascual-Manich, G., Rojo-Martinez, G., Serrano-Rios, M., Valdes, S., Vazquez, J.A., Vendrell, J.: Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 55(1), 88–93 (2012)CrossRefPubMed
5.
6.
Lopez Bastida, J., Serrano Aguilar, P., Duque Gonzalez, B.: The social and economic cost of diabetes mellitus. Aten. Prim. 29(3), 145–150 (2002)CrossRef
7.
Carral, F., Olveira, G., Salas, J., Garcia, L., Sillero, A., Aguilar, M.: Care resource utilization and direct costs incurred by people with diabetes in a Spanish hospital. Diabetes Res. Clin. Pract. 56(1), 27–34 (2002)CrossRefPubMed
8.
Alcubierre, N., Rubinat, E., Traveset, A., Martinez-Alonso, M., Hernandez, M., Jurjo, C., Mauricio, D.: A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications. Health Qual. Life Outcomes 12, 131 (2014)CrossRefPubMedPubMedCentral
9.
Rubin, R.J., Altman, W.M., Mendelson, D.N.: Health care expenditures for people with diabetes mellitus, 1992. J. Clin. Endocrinol. Metab. 78(4), 809A–809F (1994)CrossRefPubMed
10.
Brito-Sanfiel, M., Diago-Cabezudo, J., Calderon, A.: Economic impact of hypoglycemia on healthcare in Spain. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 649–660 (2010)CrossRefPubMed
11.
Ariza, M.A., Vimalananda, V.G., Rosenzweig, J.L.: The economic consequences of diabetes and cardiovascular disease in the United States. Rev. Endocr. Metab. Disord. 11(1), 1–10 (2010)CrossRefPubMed
12.
Li, R., Bilik, D., Brown, M.B., Zhang, P., Ettner, S.L., Ackermann, R.T., Crosson, J.C., Herman, W.H.: Medical costs associated with type 2 diabetes complications and comorbidities. Am. J. Manag. Care 19(5), 421–430 (2013)PubMedPubMedCentral
13.
Wirehn, A.B., Andersson, A., Ostgren, C.J., Carstensen, J.: Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet. Med. 25(6), 732–737 (2008)CrossRefPubMed
14.
Bruno, G., Picariello, R., Petrelli, A., Panero, F., Costa, G., Cavallo-Perin, P., Demaria, M., Gnavi, R.: Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr. Metab. Cardiovasc. Dis. 22(8), 684–690 (2012)CrossRefPubMed
15.
Mata, M., Antonanzas, F., Tafalla, M., Sanz, P.: The cost of type 2 diabetes in Spain: the CODE-2 study. Gac. Sanit. 16(6), 511–520 (2002)CrossRefPubMed
16.
Koster, I., Huppertz, E., Hauner, H., Schubert, I.: Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. Exp. Clin. Endocrinol. Diabetes 122(9), 510–516 (2014)CrossRefPubMed
17.
Koster, I., von Ferber, L., Ihle, P., Schubert, I., Hauner, H.: The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM study. Diabetologia 49(7), 1498–1504 (2006)CrossRefPubMed
18.
American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31(3), 596–615 (2008)CrossRef
19.
Sicras-Mainar, A., Navarro-Artieda, R., Ibanez-Nolla, J.: Clinical and economic characteristics associated with type 2 diabetes. Rev. Clin. Esp. 214(3), 121–130 (2014)CrossRefPubMed
20.
Vinagre, I., Mata-Cases, M., Hermosilla, E., Morros, R., Fina, F., Rosell, M., Castell, C., Franch-Nadal, J., Bolibar, B., Mauricio, D.: Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 35(4), 774–779 (2012)CrossRefPubMedPubMedCentral
21.
Mata-Cases, M., Roura-Olmeda, P., Berengue-Iglesias, M., Birules-Pons, M., Mundet-Tuduri, X., Franch-Nadal, J., Benito-Badorrey, B., Cano-Perez, J.F.: Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia, Spain. Int. J. Clin. Pract. 66(3), 289–298 (2012)CrossRefPubMedPubMedCentral
22.
Franch-Nadal, J., Mata-Cases, M., Vinagre, I., Patitucci, F., Hermosilla, E., Casellas, A., Bolivar, B., Mauricio, D.: Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study. Int. J. Endocrinol. 2014, 131709 (2014)CrossRefPubMedPubMedCentral
23.
Bolibar, B., Fina, A.F., Morros, R., Garcia-Gil, M.M., Hermosilla, E., Ramos, R., Rosell, M., Rodriguez, J., Medina, M., Calero, S., Prieto-Alhambra, D., Grupo SIDIAP: SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research. Med. Clin. (Barc.) 138(14), 617–621 (2012)CrossRef
24.
Garcia-Gil Mdel, M., Hermosilla, E., Prieto-Alhambra, D., Fina, F., Rosell, M., Ramos, R., Rodriguez, J., Williams, T., Van Staa, T., Bolibar, B.: Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform. Prim. Care 19(3), 135–145 (2011)PubMed
25.
Generalitat de Catalunya. Servei Català de la Salut. Registre del conjunt mínim bàsic de dades dels hospitals d’aguts (CMBD-HA). Especificacions de la validació de les dades (Àmbit AH). Available from http://​www20.​gencat.​cat/​. Accessed 31 May 2010
26.
27.
28.
Fetter, R.B., Shin, Y., Freeman, J.L., Averill, R.F., Thompson, J.D.: Case mix definition by diagnosis-related groups. Med. Care 18(2 Suppl)iii, 1–53 (1980)
29.
30.
31.
32.
Dodd, S., Bassi, A., Bodger, K., Williamson, P.: A comparison of multivariable regression models to analyse cost data. J. Eval. Clin. Pract. 12(1), 76–86 (2006)CrossRefPubMed
33.
Jackman, S.: pscl: classes and methods for R developed in the political science computational laboratory, Stanford University. Department of Political Science, Stanford University. Stanford, California. R package version 1.4.9. http://​pscl.​stanford.​edu/​ (2015)
34.
Crespo, C., Brosa, M., Soria-Juan, A., López-Alba, A., Lopez-Martínez, N., Soria, B.: Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes). Diabetologia 29(6), 182–189 (2013)
35.
Yi, Y., Philips, Z., Bergman, G., Burslem, K.: Economic models in type 2 diabetes. Curr. Med. Res. Opin. 26(9), 2105–2118 (2010)CrossRefPubMed
36.
Inoriza, J.M., Perez, M., Cols, M., Sanchez, I., Carreras, M., Coderch, J.: An analysis of the diabetic population in a Spanish rural are: morbidity profile, use of resources, complications and metabolic control. Aten. Prim. 45(9), 461–475 (2013)CrossRef
37.
38.
Gene, B.J.: The gatekeeper role of the general practitioner and the reform of the National Health Service as seen from Barcelona, Spain. Gac. Sanit. 13(5), 410–412 (1999)CrossRef
39.
Metadata
Title
Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
Authors
Manel Mata-Cases
Marc Casajuana
Josep Franch-Nadal
Aina Casellas
Conxa Castell
Irene Vinagre
Dídac Mauricio
Bonaventura Bolíbar
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 8/2016
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0742-5

Other articles of this Issue 8/2016

The European Journal of Health Economics 8/2016 Go to the issue

Original Paper

The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study

Editorial

Reimbursable drug classes and ceilings in Italy: why not only one?

Original Paper

Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature

Original Paper

Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach

Original Paper

The diffusion of generics after patent expiry in Germany

Original Paper

The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation